Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Luna

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Pharmaceutics|January 8, 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 ProtocolJuliana Salazar, María J Arranz, Javier Martin-Broto, et al.
International Journal of Environmental Research and Public Health|June 10, 2022
Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean AdultsJaime Vásquez-Gómez, César Faúndez-Casanova, Ricardo Souza de Carvalho, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 ProtocolJuliana Salazar, María J Arranz, Javier Martin-Broto, et al.
Nature Communications|October 21, 2022
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumorsJavier Martin-Broto, Andres Redondo, David S Moura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 2015
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) studyYolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, et al.
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
The Lancet. Oncology|February 19, 2020
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Josefina Cruz, Nicolas Penel, et al.
Pigment Cell & Melanoma Research|May 27, 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.
JAMA Oncology|February 21, 2020
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical TrialJavier Martin-Broto, Nadia Hindi, Antonio Lopez-Pousa, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Pharmaceutics|January 8, 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 ProtocolJuliana Salazar, María J Arranz, Javier Martin-Broto, et al.
International Journal of Environmental Research and Public Health|June 10, 2022
Estimated Oxygen Consumption with the Abbreviated Method and Its Association with Vaccination and PCR Tests for COVID-19 from Socio-Demographic, Anthropometric, Lifestyle, and Morbidity Outcomes in Chilean AdultsJaime Vásquez-Gómez, César Faúndez-Casanova, Ricardo Souza de Carvalho, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 ProtocolJuliana Salazar, María J Arranz, Javier Martin-Broto, et al.
Nature Communications|October 21, 2022
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumorsJavier Martin-Broto, Andres Redondo, David S Moura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 2015
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) studyYolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, et al.
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
The Lancet. Oncology|February 19, 2020
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Josefina Cruz, Nicolas Penel, et al.
Pigment Cell & Melanoma Research|May 27, 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.
JAMA Oncology|February 21, 2020
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical TrialJavier Martin-Broto, Nadia Hindi, Antonio Lopez-Pousa, et al.
Pageof 7